112 related articles for article (PubMed ID: 20609175)
1. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy.
Gajewski TF
Pigment Cell Melanoma Res; 2010 Oct; 23(5):580-1. PubMed ID: 20609175
[No Abstract] [Full Text] [Related]
2. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
3. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
4. Pseudoprogression and Immune-Related Response in Solid Tumors.
Chiou VL; Burotto M
J Clin Oncol; 2015 Nov; 33(31):3541-3. PubMed ID: 26261262
[No Abstract] [Full Text] [Related]
5. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
Bakacs T; Mehrishi JN
Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab, a human monoclonal antibody for treatment of unresectable or metastatic melanoma.
Wilkes GM
Oncology (Williston Park); 2011 Jul; 25(7 Suppl Nurse Ed):46-7. PubMed ID: 25373277
[No Abstract] [Full Text] [Related]
8. Beyond ipilimumab: new approaches target the immunological synapse.
Garber K
J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695
[No Abstract] [Full Text] [Related]
9. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
Queirolo P; Tanda ET
Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapies for metastatic melanoma.
Chandra S; Pavlick AC
Dermatol Clin; 2012 Jul; 30(3):517-24. PubMed ID: 22800555
[TBL] [Abstract][Full Text] [Related]
11. Melanoma vaccines: possible progress after years of frustration?
Schmidt C
J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461
[No Abstract] [Full Text] [Related]
12. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
13. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
O'Regan KN; Jagannathan JP; Ramaiya N; Hodi FS
AJR Am J Roentgenol; 2011 Aug; 197(2):W241-6. PubMed ID: 21785048
[TBL] [Abstract][Full Text] [Related]
14. What is the role of chemotherapy in the treatment of melanoma?
Megahed AI; Koon HB
Curr Treat Options Oncol; 2014 Jun; 15(2):321-35. PubMed ID: 24599525
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
16. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
Yamazaki N; Maeda Y
Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
[No Abstract] [Full Text] [Related]
17. PD-L1 expression as a potential predictive biomarker.
Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
[No Abstract] [Full Text] [Related]
18. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
[TBL] [Abstract][Full Text] [Related]
19. What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?
Donnelly OG; Melcher AA; Vile RG; Pulido J
Immunotherapy; 2012 Aug; 4(8):749-51. PubMed ID: 22947000
[No Abstract] [Full Text] [Related]
20. Highlights from the ASCO annual meeting.
Printz C
Cancer; 2013 Sep; 119(17):3104-5. PubMed ID: 24037669
[No Abstract] [Full Text] [Related]
[Next] [New Search]
